Navigation Links
Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Date:7/18/2012

197944 have also been completed, which suggest an excellent margin of safety and tolerability.

Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, added: "We are delighted to announce the successful completion of Phase I clinical studies with CNV2197944.  We now plan to shortly initiate Phase II clinical trials with CNV2197944.  This will be the second compound originating from the spin-out from GSK in October 2010 that has successfully progressed to proof of concept in the chronic pain area, which is in real need for efficacious and safe pain treatments."  

The need for new drug treatments for chronic pain

The Pain therapeutic area encompasses any disease where pain is a major symptom. The unmet medical need for patients in pain is enormous, with the greatest need being for a more effective therapy that is well tolerated and safe over a long period of time. Within the pain marketplace, current pain treatments are unsatisfactory; overall efficacy is poor (typically 1-2 point reductions on a 10 point scale) and satisfactory to less than 50% of patients. Whilst treatments, such as opioids and non-steroidal anti-inflammatory drugs, are available on the market, many patients obtain little or no relief from these existing analgesics and often such drugs are associated with adverse events, side effects and addiction concerns. This highlights the importance of Convergence Pharmaceuticals' goals to be a world leader in the development of novel, efficacious analgesics with improved pharmacology and safety profiles.

About chronic pain

Currently, more than 1.5 billion people worldwide suffer from chronic pain of varying degrees. Among all types of chronic pain, neuropathic pain stands out with approximately 3-4.5% of the global population affected, with incidence rate increasing in line with increased age of the population. With the unmet clinical need so high, the demand for better pain management therapies, add
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Convergence of Art, Science and Beer
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
4. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
6. Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City
7. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
8. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
9. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
10. Questcor Pharmaceuticals Expands Repurchase Program
11. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... (PRWEB) September 23, 2014 Marktech Optoelectronics ... deep ultra violet emitters in the 280 nm wavelength ... UV emitters which range from 280nm to 405nm. These ... water sanitation as well as curing. Mark Campito, Marktech’s ... of special interest to manufacturers is that we offer ...
(Date:9/23/2014)... September 23, 2014 The Minnesota ... developer of cellular modems , platforms and ... the Startup category for the 2014 Tekne Awards. ... at the Minneapolis Convention Center on Thursday, November ... individuals who have shown superior technology innovation and ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Pearl's Premium ... breakthrough in drought tolerant grass seed this week with ... seed. The announcement coincides with the fact that it ... Spring as many believe. , As of the ... and favorable reviews by industry experts and the media ...
(Date:9/22/2014)... by researchers at the USC Viterbi School of ... 3-D microfluidic system quickly and cheaply by simply ... Microfluidic systems are used in many fields including ... volumes of fluids for use in applications such ... diagnostic testing, and synthetic chemistry. Traditionally, microfluidic devices ...
Breaking Biology Technology:Marktech Introduces its New Line of Deep UV Emitters 2NimbeLink Named Finalist for 15th Annual Tekne Awards 2NimbeLink Named Finalist for 15th Annual Tekne Awards 3Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5
... , Chemosaturation Demonstrates Clinically Meaningful Tumor ... Delcath Systems, Inc. (NASDAQ: DCTH ... tumor (mNET) cohort of the Company,s recently completed Phase ... and Interventional Radiological Society of Europe (CIRSE) congress ...
... N.Y. A new system to be installed ... enable exciting new research possibilities across the nation ... modeling and simulation, data science, high-performance computing, and ... million grant from the National Science Foundation (NSF) ...
... All ABC Members and Members of the Herb and ... that I inform you of the passing of our ... Saturday evening, September 10, per the tribute we have ... Director, American Botanical Council, Editor, HerbalGram & HerbClip ...
Cached Biology Technology:Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 2Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 3Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 4Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 5New supercomputer to boost Rensselaer leadership in high-performance computing 2New supercomputer to boost Rensselaer leadership in high-performance computing 3New supercomputer to boost Rensselaer leadership in high-performance computing 4Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 2Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 3Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 4Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 5Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 6Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 7
(Date:9/23/2014)... fragments called "jumping genes" that insert themselves into DNA ... phenomenon can result in age-related diseases such as cancer. ... that the "jumping genes" in mice become active as ... them in check in order to take on another ... Nature Communications , Professor of Biology Vera Gorbunova ...
(Date:9/22/2014)... new American Cancer Society study suggests that participants ... known as the food stamp program, had lower ... The authors say the findings emphasize the need ... quality of SNAP participants. , The SNAP program ... the resources to obtain a nutritionally adequate diet. ...
(Date:9/22/2014)... researchers are studying a potential new treatment that reverses ... which scars develop in the lungs and severely hamper ... which is delivered to lung tissue intravenously. In mouse ... fibrosis after several days. , The findings were ... Medicine . , "The mimic, when injected into the ...
Breaking Biology News(10 mins):A multi-function protein is key to stopping genomic parasites from 'jumping' 2Federal food program puts food on the table, but dietary quality could be improved 2Reversing the effects of pulmonary fibrosis 2
... the Upper Paraguay River and its tributaries, is the largest ... of organisms and it is an ark for large populations ... Pantanal fulfills a large range of ecosystem services that are ... seasonal floodplain system, plants, animals, and local human populations show ...
... cover all from the historical aspects of the beaver ... the development of reintroduced or recovering populations, consequences of ... beavers, relationship with animal and plant communities on land ... the high degree to which the beaver is able ...
... (Nicols Prez Hidalgo and M. Pilar Mier Durante) have ... Matsumura ) in Madrid, Spain from a photography displayed ... ) (ngel Umaran). The results have been published recently ... are available for free download. "This discovery is ...
Cached Biology News:
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
...
... versatile enclosures are designed ... or other process gas ... environment. HEPA filtration, heating/cooling, ... modules also available, along ...
... Staccato Series of systems provide fast and ... , genomics, proteomics and drug development laboratories. ... configurations; Mini Workstation Series, Application Series and ... Station is a remarkably compact system for ...
Biology Products: